Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): A double-blind, cross-over study in healthy volunteers

Pharmacopsychiatry

Volumn 38, Issue 6, 2005, Pages 301-311

  Gouzoulis Mayfrank, Euphrosyne ^a,d   Heekeren, K ^a,b   Neukirch, A ^a,b   Stoll, M ^b   Stock, C ^b   Obradovic, M ^c   Kovar, K A ^c  

^a UNIVERSITY OF COLOGNE   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d Department of Psychiatry and Psychotherapy ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMATE RECEPTOR ANTAGONIST; KETAMINE; KETANEST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; N,N DIMETHYLTRYPTAMINE; SEROTONIN 2A AGONIST;

ADULT; APATHY; ARTICLE; ATTENTION DEFICIT DISORDER; AUDITORY HALLUCINATION; BEHAVIOR DISORDER; CATATONIA; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COMMUNICATION DISORDER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HEALTH STATUS; HUMAN; HYPOMIMIA; ILLUSION; MALE; MOOD DISORDER; PARANOIA; PERCEPTION DEAFNESS; PERCEPTION DISORDER; POVERTY OF SPEECH; PRIORITY JOURNAL; PSYCHOLOGY; PSYCHOMOTOR POVERTY; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SENSORY DYSFUNCTION; THOUGHT DISORDER; TOUCH; VERBAL COMMUNICATION; VISUAL DISORDER; VISUAL HALLUCINATION; VOLUNTEER; WITHDRAWAL SYNDROME;

ADULT; COGNITION; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HALLUCINATIONS; HALLUCINOGENS; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; KETAMINE; MALE; MIDDLE AGED; N,N-DIMETHYLTRYPTAMINE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIC PSYCHOLOGY; STEREOISOMERISM;

EID: 29144513466     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-916185     Document Type: Article

References (81)

1. Abi-Saab WM, D'Souza DC, Moghaddam B, Krystal JH. The NMDA antagonist model for schizophrenia: promise and pitfalls. Pharmacopsychiatry 1998; 31(Suppl.): 104-109
2. Adler CM, Goldberg TE, Malhotra AK, Pickar D, Breier A. Effects of ketamine on thought disorder, working memory and semantic memory in healthy volunteers. Biol Psychiatry 1998; 43: 811-816
3. Anand A, Charney DS, Oren DA, Berman RM, Hu XS, Cappiello A, Krystal JH. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-d-aspartate receptor antagonists. Arch Gen Psychiatry 2000; 57: 270-276
4. Andreasen NC. Scale for the assessment of positive symptoms SAPS. Dep. of Psychiatry, University of Iowa, Iowa City, Copyright by Andreasen NC: 1984
5. Andreasen NC. Scale for the assessment of negative symptoms SANS. Dep. of Psychiatry, University of Iowa, Iowa City, Copyright by Andreasen NC; : 1984
6. Beringer K. Der Meskalinrausch. Heidelberg, Berlin: Springer, 1927
7. Breier A, Malhotra AK, Pinals DA, Weisenfeld NI, Pickar D. Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Am J Psychiatry 1997; 154: 805-811
8. Carpenter WT. The schizophrenia ketamine challenge study debate. Biol Psychiatry 1999; 46: 1081-1091
9. Carter OL, Pettigrew JD, Burr DC, Alais D, Hasler F, Vollenweider FX. Psilocybin impairs high-level but not low-level motion perception. Neuroreport 2004; 15: 1947-1951
10. Carter OL, Pettigrew JD, Hasler F, Wallis GM, Liu GB, Hell D, Vollenweider FX. Modulating the rate and rhythmicity of perceptual rivalry alternations with the mixed 5-HT2A and 5-HT1A agonist psilocybin. Neuropsychopharmacology. 2005; 30: 1154-1162
11. Dittrich A. Aetiologie-unabhängige Strukturen veraenderter Wachbewusstseinszustaende. Stuttgart: Enke, 1985
12. Dittrich A, von Arx S, Staub S. International study on altered states of consciousness (ISASC). Summary of the results. German J Psychol 1985; 9: 319-339
13. Duncan EJ, Madonick SH, Parwani A, Angrist B, Rajan R, Chakravorty S, Eiferen TR, Szilagyi S, Stephanides M, Chappell PB, Gonzenbach S, Ko GN, Rotrosen JP. Clinical and sensorimotor gating effects of ketamine in normals. Neuropsychopharmacology 2001; 25: 72-83
14. D'Souza DC, Berman RM, Krystal JH, Charney DS. Symptom provocation studies in psychiatric disorders: scientific value, risks, and future. Biol Psychiatry 1999; 46: 1060-1080
15. Ellis H. Mescal: A new artificial paradise. Annual report of the Smithsonian. Institution, 1897: 537-548
16. Feng N, Vollenweider FX, Minder EL, Rentsch K, Grampp T, Vonderschmitt DJ. Development of a gas chromatography-mass spectrometry method for determination of ketamine in plasma and its application to human samples. Ther Drug Monit 1995; 17: 95-100
17. Frecska E, White KD, Luna LE. Effects of ayahuasca on binocular rivalry with dichoptic stimulus alternation. Psychopharmacology 2004; 173: 79-87
18. Freedman B, Chapman J. Early subjective experience in schizophrenic episodes. J Abnormal Psychol 1973; 82: 46-54
19. Gouzoulis E, Hermle L, Sass H. Psychedelic experiences at the beginning of acute endogenous psychotic episodes. Nervenarzt 1994; 65: 198-201
20. Gouzoulis-Mayfrank E, Habermeyer E, Hermle L, Steinmeyer AM, Kunert J, Sass H. Hallucinogenic drug induced states resemble acute endogenous psychotic episodes: Results of an empirical study. Eur Psychiatry 1998; 13: 399-406
21. Gouzoulis-Mayfrank E, Heekeren K, Thelen B, Lindenblatt H, Kovar KA, Sass H, Geyer MA. Effects of the hallucinogen psilocybin on habituation and prepulse inhibition of the startle reflex in humans. Behav Pharmacol. 1998; 9: 561-566
22. Gouzoulis-Mayfrank E, Hermle L, Thelen B, Sass H. History, rationale and potential of experimental hallucinogenic drug research in psychiatry. Pharmacopsychiatry 1998; 31(Suppl. 2): 63-68
23. Gouzoulis-Mayfrank E, Schneider F, Spitzer M, Thelen B, Sass H. Methodological issues of human experimental research with hallucinogens. Pharmacopsychiatry 1998; 31(Suppl. 2): 114-118
24. Gouzoulis-Mayfrank E, Schreckenberger M, Sabri O, Arning C, Thelen B, Spitzer M, Kovar KA, Bull U, Sass H. Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with [18F]FDG. Neuropsychopharmacology 1999; 20: 565-581
25. Gouzoulis-Mayfrank E, Thelen B, Habermeyer E, Kunert HJ, Kovar KA, Hermle L, Spitzer M, Sass H. Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers. Results of an experimental double-blind placebo-controlled study. Psychopharmacology 1999; 142: 41-50
26. Gouzoulis-Mayfrank E, Thelen B, Maier S, Habermeyer E, Kovar K-A, Sass H, Spitzer M. Effects of the hallucinogen psilocybin on covert orienting of visual attention in humans. Neuropsychobiology 2002; 45: 205-212
27. Guillermain Y, Micallef J, Possamai C, Blin O, Hasbroucq T. N-methyl-D-aspartate receptors and information processing: human choice reaction time under a subanaesthetic dose of ketamine. Neurosci Lett 2001; 303: 29-32
28. Hasler F, Grimberg U, Benz MA, Huber T, Vollenweider FX. Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study. Psychopharmacology 2004; 172: 145-156
29. Hermle L, Fünfgeld M, Oepen G, Botsch H, Borchardt D, Gouzoulis E, Fehrenbach RA, Spitzer M. Mescaline-induced psychopathological, neuropsychological and neurometabolic effects in normal subjects. Experimental psychosis as a tool for psychiatric research. Biol Psychiatry 1992; 32: 976-991
30. Hetem LAB, Danion JM, Diemunsch P, Brandt C. Effect of a subanesthetic dose of ketamine on memory and conscious awareness in healthy volunteers. Psychopharmacology 2000; 152: 283-288
31. Holcomb HH, Lahti AC, Medoff DR, Weiler M, Tamminga CA. Sequential regional cerebral blood flow brain scans using PET with H2(15)O demonstrate ketamine actions in CNS dynamically. Neuropsychopharmacology 2001; 25: 165-172
32. Hollister LE. Drug-induced psychoses and schizophrenic reactions: a critical comparison. Ann N Y Acad Sci 1962; 96: 80-92
33. Idvall J, Ahlgren I, Aronsen KR, Stenberg P. Ketamine infusions: pharmacokinetics and clinical effects. Br J Anaesth 1979; 51: 167-1173
34. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991; 148: 1301-1308
35. Kegeles LS, Abi-Dargham A, Zea-Ponce Y, Rodenhiser-Hill J, Mann JJ, Van Heertum RL, Cooper TB, Carlsson A, Laruelle M. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol Psychiatry 2000; 48: 627-640
36. Kegeles LS, Martinez D, Kochan LD, Hwang DR, Huang Y, Mawlawi O, Suckow RF, Van Heertum RL, Laruelle M. NMDA antagonist effects on striatal dopamine release: positron emission tomography studies in humans. Synapse 2002; 43: 19-29
37. Klosterkotter J, Hellmich M, Steinmeyer EM, Schultze-Lutter F. Diagnosing schizophrenia in the initial prodromal phase. Arch Gen Psychiatry 2001; 58: 158-164
38. Kreitschmann-Andermahr I, Rosburg T, Demme U, Gaser E, Nowak H, Sauer H. Effect of ketamine on the neuromagnetic mismatch field in healthy humans. Brain Res Cogn Brain Res 2001; 12: 109-116
39. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB, Charney DS. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994; 51: 199-214
40. Krystal JH, Karper LP, Bennett A, D'Souza DC, Abi-Dargham A, Morrissey K, Abi-Saab D, Bremner JD, Bowers MB, Jr., Suckow RF, Stetson P, Heninger GR, Charney DS. Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans. Psychopharmacology 1998; 135: 213-229
41. Krystal JH, Petrakis IL, Webb E, Cooney NL, Karper LP, Namanworth S, Stetson P, Trevisan LA, Charney DS. Dose-related ethanol-like effects of the NMDA antagonist, ketamine, in recently detoxified alcoholics. Arch Gen Psychiatry 1998; 55: 354-360
42. Krystal JH, Bennett A, Abi-Saab D, Belger A, Karper LP, D'Souza DC, Lip-schitz D, Abi-Dargham A, Charney DS. Dissociation of ketamine effects on rule acquisition and rule implementation: possible relevance to NMDA receptor contributions to executive cognitive functions. Biol Psychiatry 2000; 47: 137-143
43. Lahti AC, Holcomb HH, Medoff DR, Tamminga CA. Ketamine activates psychosis and alters limbic blood flow in schizophrenia. NeuroReport 1995; 6: 869-872
44. Lahti AC, Koffel B, LaPorte D, Tamminga CA. Subanaesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 1995; 13: 9-19
45. Lahti AC, Weiler MA, Tamara Michaelidis BA, Parwani A, Tamminga CA. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 2001; 25: 455-467
46. LaPorte DJ, Lahti AC, Koffel B, Tamminga CA. Absence of ketamine effects on memory and other cognitive functions in schizophrenic patients. J Psychiat Res 1996; 30: 321-330
47. Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelley R. Study of a new schizophrenomimetic drug - sernyl. Am Med Assoc Arch Neurological Psychiatry 1959; 81: 363-369
48. Malhotra AK, Pinals DA, Weingartner H, Sirocco K, Missar CD, Pickar D, Breier A. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 1996; 14: 301-307
49. Malhotra AK, Adler CM, Kennison SD, Elman I, Pickar D, Breier A. Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: a study with ketamine. Biol Psychiatry 1997; 42: 664-668
50. Medoff DR, Holcomb HH, Lahti AC, Tamminga CA. Probing the human hippocampus using rCBF: contrasts in schizophrenia. Hippocampus 2001; 11: 543-550
51. Micallef J, Guillermain Y, Tardieu S, Hasbroucq T, Possamai C, Jouve E, Blin O. Effects of subanesthetic doses of ketamine on sensorimotor information processing in healthy subjects. Clin Neuropharmacol 2002; 25: 101-106
52. Mitchell SW. The effects of Anhalonium Lewinii (the mescal button). BMJ 1896; 2: 1625-1629
53. Morgan CJA, Mofeez A, Brandne B, Bromley L, Curran HV. Acute effects of ketamine on memory systems and psychotic symptoms in healthy volunteers. Neuropsychopharmacology 2004; 29: 208-218
54. Newcomer JW, Farber NB, Jevtovic-Todorovic V, Selke G, Melson AK, Hershey T, Craft S, Olney JW. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology 1999; 20: 106-118
55. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995; 52: 998-1007
56. Oranje B, van Berckel BN, Kemner C, van Ree JM, Kahn RS, Verbaten MN. The effects of a sub-anaesthetic dose of ketamine on human selective attention. Neuropsychopharmacology 2000; 22: 293-302
57. Øye N, Hustveit O, Moberg ER, Pausen O, Skoglund LA. The chiral forms of ketamine as probes for NMDA receptor function in humans. In Kameyama T, Nabeshima T, Domino ES, editors. NMDA receptor related agents: Biochemistry, Pharmacology and Behavior Ann Arbor: NPP Books, 1991: p 381-389
58. Øye N, Paulsen O, Maurset A. Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors. Journal of Pharmacology and Experimental Therapeutics 1992; 260: 1209-1213
59. Pechnick RN, Ungerleider JT. Hallucinogens. In Lowinson JH, Ruiz P, Millman RB, Langrod JG, editors. Substance Abuse. A comprehensive textbook, 3rd ed Baltimore, Maryland:: Williams and Wilkins, 1997: p 230-238
60. Rosenbaum G, Cohen BD, Luby ED, Gottlieb JS, Yelen D. Comparison of Sernyl with other drugs. Arch Gen Psychiatry 1959; 1: 113-118
61. Riba J, Rodriguez-Fornells A, Urbano G, Morte A, Antonijoan R, Montero M, Callaway JC, Barbanoj MJ. Subjective effects and tolerability of the South American psychoactive beverage Ayahuasca in healthy volunteers. Psychopharmacology 2001; 154: 85-95
62. Riba J, Anderer P, Jané F, Saletu B, Barbanoj MJ. Effects of the South American psychoactive beverage ayahuasca on regional brain electrical activity in humans: a functional neuroimaging study using low-resolution electromagnetic tomography. Neuropsychobiology 2004; 50: 89-101
63. Smith GS, Schloesser R, Brodie JD, Dewey SL, Logan J, Vitkun SA, Simkowitz P, Hurley A, Cooper T, Volkow ND, Cancro R. Glutamate modulation of dopamine measured in vivo with positron emission tomography (PET) and 11C-raclopride in normal human subjects. Neuropsychopharmacology 1998; 18: 18-25
64. Snyder SH. Psychotogenic drugs as models for schizophrenia. Neuropsychopharmacology 1988; 1: 197-199
65. Spitzer M, Thimm M, Hermle L, Holzman P, Schneider F, Gouzoulis-Mayfrank E, Kischka U, Kovar K-A. Increased activation of indirect semantic associations under psilocybin. Biol Psychiatry 1996; 39: 1055-1057
66. Stockings GT. A clinical study of the mescaline psychosis, with special reference to the mechanism of the genesis of schizophrenic and other psychotic states. J Ment Sci 1940; 86: 29-47
67. Strassman RJ, Qualls CR. Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic and cardiovascular effects. Arch Gen Psychiatry 1994; 51: 85-97
68. Strassman RJ, Qualls CR, Uhlenhuth EH, Kellner R. Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale. Arch Gen Psychiatry 1994; 51: 98-108
69. Strassman RJ, Qualls CR, Berg LM. Differential tolerance to biological and subjective effects of four closely spaced doses of N,N-dimethyltryptamine in humans. Biol Psychiatry 1996; 39: 784-795
70. Umbricht D, Schmid L, Koller R, Vollenweider FX, Hell D, Javitt DC. Ke-tamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia. Arch Gen Psychiatry 2000; 57: 1139-1147
71. Umbricht D, Koller R, Vollenweider FX, Schmid L. Mismatch negativity predicts psychotic experiences induced by NMDA receptor antagonist in healthy volunteers. Biol Psychiatry 2002; 51: 400-406
72. Umbricht D, Vollenweider FX, Schmid L, Grubel C, Skrabo A, Huber T, Koller R. Effects of the 5-HT2A agonist psilocybin on mismatch negativity generation and AX-continuous performance task: implications for the neuropharmacology of cognitive deficits in schizophrenia. Neuropsychopharmacology 2003; 28: 170-181
73. Vollenweider FX. Advances and pathophysiological models of hallucinogenic drug actions in humans: a preamble to schizophrenia research. Pharmacopsychiatry 1998; 31 2: 92-103
74. Vollenweider FX, Geyer MA. A systems model of altered consciousness: integrating natural and drug-induced psychoses. Brain Res Bull 2001; 56: 495-507
75. Vollenweider FX, Antonini A, Leenders KL, Oye I, Hell D, Angst J. Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET). Eur Neuropsychopharmacology 1997; 7: 25-38
76. Vollenweider FX, Leenders KL, Scharfetter C, Antonini A, Maguire P, Missimer J, Angst J. Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG). Eur Neuropsychopharmacology 1997; 7: 9-24
77. Vollenweider FX, Leenders KL, Scharfetter C, Maguire P, Stadelmann O, Angst J. Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology 1997; 16: 357-372
78. Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Babler A, Vogel H, Hell D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 1998; 9: 3897-3902
79. Vollenweider FX, Vontobel P, Hell D, Leenders KL 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man - a PET study with [HC]raclopride. Neuropsychopharmacology 1999; 20: 424-433
80. Vollenweider FX, Vontobel P, Oye I, Hell D, Leenders KL. Effects of (S)-ketamine on striatal dopamine: a [11C]raclopride PET study of a model psychosis in humans. J Psychiatr Res 2000; 34: 35-43
81. Weiler MA, Thaker GK, Lahti AC, Tamminga CA. Ketamine effects on eye movements. Neuropsychopharmacology 2000; 23: 645-653